CA2775354C - Antimalarial agents that are inhibitors of dihydroorotate dehydrogenase - Google Patents

Antimalarial agents that are inhibitors of dihydroorotate dehydrogenase Download PDF

Info

Publication number
CA2775354C
CA2775354C CA2775354A CA2775354A CA2775354C CA 2775354 C CA2775354 C CA 2775354C CA 2775354 A CA2775354 A CA 2775354A CA 2775354 A CA2775354 A CA 2775354A CA 2775354 C CA2775354 C CA 2775354C
Authority
CA
Canada
Prior art keywords
compound
mmol
pharmaceutically acceptable
synthesis
triazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2775354A
Other languages
English (en)
French (fr)
Other versions
CA2775354A1 (en
Inventor
Margaret Phillips
Pradipsinh K. Rathod
Susan A. Charman
David Floyd
Jeremy Burrows
David Matthews
Alka Marwaha
Ramesh Gujjar
Jose Coteron-Lopez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicines for Malaria Venture
WASHINGTON, University of
The University of Texas System
Original Assignee
Medicines for Malaria Venture
WASHINGTON, University of
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicines for Malaria Venture, WASHINGTON, University of, The University of Texas System filed Critical Medicines for Malaria Venture
Publication of CA2775354A1 publication Critical patent/CA2775354A1/en
Application granted granted Critical
Publication of CA2775354C publication Critical patent/CA2775354C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2775354A 2009-09-29 2010-09-28 Antimalarial agents that are inhibitors of dihydroorotate dehydrogenase Expired - Fee Related CA2775354C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24686309P 2009-09-29 2009-09-29
US61/246,863 2009-09-29
PCT/US2010/050532 WO2011041304A2 (en) 2009-09-29 2010-09-28 Antimalarial agents that are inhibitors of dihydroorotate dehydrogenase

Publications (2)

Publication Number Publication Date
CA2775354A1 CA2775354A1 (en) 2011-04-07
CA2775354C true CA2775354C (en) 2019-01-15

Family

ID=43826848

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2775354A Expired - Fee Related CA2775354C (en) 2009-09-29 2010-09-28 Antimalarial agents that are inhibitors of dihydroorotate dehydrogenase

Country Status (15)

Country Link
US (1) US9238653B2 (enExample)
EP (1) EP2483274B1 (enExample)
JP (1) JP5818266B2 (enExample)
CN (1) CN102741255B (enExample)
BR (1) BR112012007179B8 (enExample)
CA (1) CA2775354C (enExample)
DK (1) DK2483274T3 (enExample)
ES (1) ES2527835T3 (enExample)
HR (1) HRP20150066T1 (enExample)
ME (1) ME02020B (enExample)
PL (1) PL2483274T3 (enExample)
PT (1) PT2483274E (enExample)
SI (1) SI2483274T1 (enExample)
SM (1) SMT201500071B (enExample)
WO (1) WO2011041304A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6392352B2 (ja) * 2013-12-19 2018-09-19 ノバルティス アーゲー リーシュマニア症などの寄生虫病を処置するための原生動物のプロテアソーム阻害剤としての［１，２，４］トリアゾロ［１，５−ａ］ピリミジン誘導体
EP3072894A1 (en) 2015-03-26 2016-09-28 Board Of Regents Of the University Of Texas System New substituted triazolopyrimidines as anti-malarial agents
EP3254679A1 (de) 2016-06-09 2017-12-13 Christian-Albrechts-Universität zu Kiel Wirkstoffe gegen protozoen und bakterien
WO2018071282A1 (en) * 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
EP3548035A4 (en) 2016-11-30 2020-07-22 Case Western Reserve University COMBINATIONS OF 15-PGDH INHIBITORS WITH CORCOSTEROIDS AND / OR TNF INHIBITORS AND THEIR USES
CN110573154A (zh) 2017-02-06 2019-12-13 卡斯西部储备大学 调节短链脱氢酶活性的组合物和方法
JP7178360B2 (ja) 2017-04-07 2022-11-25 ケース ウエスタン リザーブ ユニバーシティ 冠状動脈障害を治療するための短鎖型デヒドロゲナーゼ活性の阻害剤
WO2020106998A1 (en) 2018-11-21 2020-05-28 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase activity
EP3842100A1 (en) * 2019-12-24 2021-06-30 The Board Of Regents Of The University Of Texas System Anti-malarial agents
AU2021224268A1 (en) 2020-02-21 2022-09-15 Case Western Reserve University Compositions and methods for treating renal injury

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU208693B (en) * 1991-02-22 1993-12-28 Egyt Gyogyszervegyeszeti Gyar Process for producing 1,2,4-triazolo (1,5-a) pyrimidinis derivatives and their carbicycli-tetrahydro-thiofurane-tetrahydrothiopyrane-, or tetrahydropyridine- condensated derivatives or medical preparatives containing them
US5478825A (en) 1991-02-22 1995-12-26 Egis Gyogyszergyar 5-(substituted amino)-1,2,4-triazolo (1,5-A) pyrimidine derivatives
US8490825B2 (en) 1999-12-08 2013-07-23 Metal Container Corporation Can lid closure and method of joining a can lid closure to a can body
CZ294535B6 (cs) * 2001-08-02 2005-01-12 Ústav Experimentální Botaniky Avčr Heterocyklické sloučeniny na bázi N6-substituovaného adeninu, způsoby jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující
WO2007149211A1 (en) * 2006-06-22 2007-12-27 Board Of Regents, University Of Texas System Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
CA2676138A1 (en) * 2007-01-26 2008-08-07 Irm Llc Compounds and compositions as kinase inhibitors
WO2009082691A1 (en) 2007-12-21 2009-07-02 Board Of Regents, University Of Texas System Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity

Also Published As

Publication number Publication date
HK1174639A1 (en) 2013-06-14
PL2483274T3 (pl) 2015-04-30
CN102741255A (zh) 2012-10-17
CA2775354A1 (en) 2011-04-07
BR112012007179A8 (pt) 2018-01-23
WO2011041304A3 (en) 2011-08-04
US20120302586A1 (en) 2012-11-29
EP2483274A4 (en) 2013-03-06
PT2483274E (pt) 2015-02-04
WO2011041304A2 (en) 2011-04-07
SMT201500071B (it) 2015-05-05
BR112012007179B1 (pt) 2020-12-01
SI2483274T1 (sl) 2015-02-27
BR112012007179B8 (pt) 2021-05-25
BR112012007179A2 (pt) 2017-07-25
ME02020B (me) 2015-05-20
DK2483274T3 (en) 2015-01-19
EP2483274A2 (en) 2012-08-08
JP2013506004A (ja) 2013-02-21
US9238653B2 (en) 2016-01-19
ES2527835T3 (es) 2015-01-30
JP5818266B2 (ja) 2015-11-18
HRP20150066T1 (hr) 2015-02-27
CN102741255B (zh) 2015-10-07
EP2483274B1 (en) 2014-10-29

Similar Documents

Publication Publication Date Title
JP5818266B2 (ja) ジヒドロオロット酸デヒドロゲナーゼの阻害剤である抗マラリア剤
US9216983B2 (en) Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
US9840515B2 (en) Protein kinase D inhibitors
US20080096903A1 (en) Sulfamoyl-containing derivatives and uses thereof
US20100298557A1 (en) Pyrazolopyrimidine compound
van den Berg et al. Inhibition of monoamine oxidase B by selected benzimidazole and caffeine analogues
US10464932B2 (en) Iminothiadiazinane dioxide derivatives as plasmepsin V inhibitors
US9695193B2 (en) Inhibitors of Plasmodium falciparum equilibrative nucleoside transporter type I as anti-parasitic compounds
BG66141B1 (bg) Бета - карболинови производни като инхибитори на фосфодиестераза
SK158299A3 (en) Novel cyclic diamine compounds and medicine containing the same
JP2010522226A (ja) 酵素ｐｄｅ７及び／又はｐｄｅ４の二重阻害化合物、薬剤組成物および利用法
WO2016016365A1 (en) Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US20080027079A1 (en) Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
ES2919124T3 (es) Agentes antipalúdicos
EP3380476A1 (en) Fused pyrimidines as isoform selective phosphoinositide-3-kinase-alpha inhibitors and process for preparation thereof
FR2711992A1 (fr) Nouveaux dérivé hétérocycliques, procédé de préparation et composition pharmaceutique les contenant.
Dal Piaz et al. Isoxazolo [3, 4-d] pyridazinones and analogues as Leishmania mexicana PDE inhibitors
HK1174639B (en) Antimalarial agents that are inhibitors of dihydroorotate dehydrogenase
WO2014016789A1 (en) Pyrazolo[3,4-d]pyrimidin-4(5h)-one derivatives as pde9 inhibitors
KR20030072251A (ko) 신규 퓨린 유도체
US8815846B2 (en) Family of antichagasics derived from imidazo[4,5-C][1,2,6]thiadiazine 2,2-dioxide

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150707

MKLA Lapsed

Effective date: 20220329

MKLA Lapsed

Effective date: 20200928